Monthly ART Injections Top Pills for HIV Patients With Adherence Problems
Long-acting cabotegravir/rilpivirine (Cabenuva; CAB/RPV-LA) appeared superior to daily oral antiretroviral therapy (ART) in maintaining viral load suppression for people living with HIV who have trouble adhering to oral ART, according to an interim analysis of a phase III trial. At 52 weeks, numerically fewer patients assigned to monthly injections of CAB/RPV-LA experienced regimen failure — […]